Jun 19 2010
Spectral Molecular Imaging (SMI) has released a new Investor Information Brief that highlights the company’s strategies to design a range of optical imaging systems for early detection of cancer. The Brief also includes details about SMI’s patented optical imaging technology.
SMI is utilizing the optical imaging technology to develop a series of imaging systems. These imaging systems can help detect major diseases and evaluate the tissue status during or after the surgical procedures.
SMI’s hyperspectral imaging technology is developed to facilitate real-time analysis and identification of the tissue, cellular and molecular characteristics to detect early-stage cancer diseases quickly and accurately. In addition to the hyperspectral imaging technology, the company is also developing another imaging device called the MelaSpect to help detect early-stage skin cancer.
At present, dermatologists depend on visual examinations to detect suspicious tissue mass. Such standard examinations may provide incorrect or ambiguous diagnosis.
SMI is also leveraging its advanced spectral imaging technology to design products that may evaluate the tissue status during major and minor surgeries.
SMI’s Chairman, Daniel L. Farkas, stated that the company’s proprietary technology provides solutions for present medical needs and will become more prominent within the next 10 years.
SMI is a subsidiary company of Cascade Technologies.